MXPA06013649A - Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel. - Google Patents

Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.

Info

Publication number
MXPA06013649A
MXPA06013649A MXPA06013649A MXPA06013649A MXPA06013649A MX PA06013649 A MXPA06013649 A MX PA06013649A MX PA06013649 A MXPA06013649 A MX PA06013649A MX PA06013649 A MXPA06013649 A MX PA06013649A MX PA06013649 A MXPA06013649 A MX PA06013649A
Authority
MX
Mexico
Prior art keywords
independently hydrogen
alkyl
compounds
skin disorders
inflammatory skin
Prior art date
Application number
MXPA06013649A
Other languages
English (en)
Spanish (es)
Inventor
Jack A Dejovin
Thomas M Rossi
Original Assignee
Sansrosa Pharmaceutical Dev In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Sansrosa Pharmaceutical Dev In filed Critical Sansrosa Pharmaceutical Dev In
Publication of MXPA06013649A publication Critical patent/MXPA06013649A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA06013649A 2004-05-25 2005-05-25 Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel. MXPA06013649A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
PCT/US2005/018288 WO2005115395A2 (en) 2004-05-25 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Publications (1)

Publication Number Publication Date
MXPA06013649A true MXPA06013649A (es) 2007-07-09

Family

ID=35451386

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013649A MXPA06013649A (es) 2004-05-25 2005-05-25 Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.

Country Status (15)

Country Link
EP (2) EP1761266B1 (cg-RX-API-DMAC7.html)
JP (2) JP4955543B2 (cg-RX-API-DMAC7.html)
KR (1) KR101257046B1 (cg-RX-API-DMAC7.html)
CN (2) CN104490884A (cg-RX-API-DMAC7.html)
AU (1) AU2005247467B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511519A (cg-RX-API-DMAC7.html)
CA (2) CA2567401C (cg-RX-API-DMAC7.html)
DK (1) DK1761266T3 (cg-RX-API-DMAC7.html)
ES (2) ES2424644T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013649A (cg-RX-API-DMAC7.html)
NZ (1) NZ552325A (cg-RX-API-DMAC7.html)
PL (1) PL1761266T3 (cg-RX-API-DMAC7.html)
PT (1) PT1761266E (cg-RX-API-DMAC7.html)
SI (1) SI1761266T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005115395A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
EP2444068B2 (en) 2010-10-21 2017-12-06 Galderma S.A. Brimonidine gel composition
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
DK3093017T3 (da) * 2010-11-16 2021-04-06 Allergan Inc Farmaceutisk sammensætning omfattende (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol til behandling af optisk neuropati
CN107007546A (zh) * 2011-02-15 2017-08-04 阿勒根公司 用于治疗红斑痤疮的症状的羟甲唑啉药物乳膏组合物
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
RU2014119879A (ru) * 2011-10-19 2015-11-27 Галдерма С.А. Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
RU2015148910A (ru) * 2013-05-06 2017-06-13 Аллерган, Инк. Альфа-адренергические агонисты для лечения повреждения тканей
AU2014292879A1 (en) * 2013-07-26 2016-02-11 Galderma Research & Development Compositions for treating skin thickening
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
EP3054935B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
WO2017007910A1 (en) 2015-07-09 2017-01-12 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
US20220218590A1 (en) * 2019-05-14 2022-07-14 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives
CA3190833A1 (en) * 2020-08-26 2022-03-03 Michael Mcdonald CROWLEY Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
KR20010032435A (ko) * 1997-11-24 2001-04-25 데이비드 엠 모이어 5-(2-이미다졸리닐아미노)벤즈이미다졸 유도체, 그의 제조및 대사 안정성이 개선된 알파-아드레날린수용체아고니스트로서의 그의 용도
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (cg-RX-API-DMAC7.html) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
EP1761266A4 (en) 2009-11-11
EP2481412A1 (en) 2012-08-01
AU2005247467B2 (en) 2010-12-02
JP2012072176A (ja) 2012-04-12
CN104490884A (zh) 2015-04-08
CA2567401A1 (en) 2005-12-08
EP1761266A2 (en) 2007-03-14
CA2824612C (en) 2016-08-16
CA2567401C (en) 2013-11-12
PL1761266T3 (pl) 2013-09-30
WO2005115395A2 (en) 2005-12-08
NZ552325A (en) 2010-11-26
JP5547705B2 (ja) 2014-07-16
KR101257046B1 (ko) 2013-04-22
CA2824612A1 (en) 2005-12-08
EP2481412B1 (en) 2017-09-27
EP1761266B1 (en) 2013-05-08
WO2005115395A3 (en) 2009-04-09
KR20070032716A (ko) 2007-03-22
ES2647618T3 (es) 2017-12-22
SI1761266T1 (sl) 2013-08-30
JP2008500356A (ja) 2008-01-10
ES2424644T3 (es) 2013-10-07
BRPI0511519A (pt) 2007-12-26
CN101426502A (zh) 2009-05-06
AU2005247467A1 (en) 2005-12-08
PT1761266E (pt) 2013-06-04
DK1761266T3 (da) 2013-08-05
JP4955543B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
MXPA06013649A (es) Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
WO2004105703A3 (en) Compounds, formulations, and methods for treating or preventing rosacea
PH12022551981A1 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
TW200722087A (en) Treatment of dermatological diseases and pruritus
IL151695A0 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
DE602004011401D1 (de) Benzazepinderivate als histamin-h3-antagonisten
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
SG157231A1 (en) Substituted p-diaminobenzene derivatives
WO2001078706A3 (en) Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
GB0513886D0 (en) Novel compounds
WO2007013936A3 (en) Method for treating nervous system disorders and conditions
HRP20040421B1 (hr) INHIBICIJA VIRUSA n-DOKOZANOLOM
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
DK1756066T3 (da) Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet
DE602004022308D1 (de) Polyetherbrevetoxinderivate als behandlung für zystische fibrose, mukoziliäre dysfunction und lungenkrankheiten
CY1116690T1 (el) Τοπικη συνθεση για χρηση στην θεραπεια της ερυθροτητας που επαγεται απο την ροδοχρωμη ακμη
SG126014A1 (en) Treatment of asthma

Legal Events

Date Code Title Description
FC Refusal